Researchers at the 47th Society of Critical Care Medicine reported this week that Hill-Rom‘s (NYSE:HRC) Metaneb System may help reduce the incidence of post-operative pulmonary complications in high-risk patients. A 419-patient study found that patients using the Metaneb System combined with standard respiratory therapy spent 1.6 fewer days in the hospital on average compared to the […]
Intersect ENT posts Street-beating Q4, full-year sales, earnings
Shares in Intersect ENT (NSDQ:XENT) rose today after the medical device maker topped expectations on Wall Street with its fourth quarter and full-year financial results. The Menlo Park, Calif.-based company posted a net loss of -$3.2 million, or-11¢ per share, on sales of $29.5 million for the three months ended Dec. 31, for sales growth of 22% […]
Dexcom beats The Street with Q4 sales, earnings
Dexcom (NSDQ:DXCM) beat expectations on Wall Street with its fourth quarter and full year financial results, growing its quarterly revenue 29% compared to the same period last year. The San Diego, Calif.-based company posted a net loss of -$9.4 million, or -11¢ per share, on sales of $221 million for the 3 months ended Dec. 31. […]
Facing legal woes, PixarBio takes aim at InVivo
PixarBio (OTC:PXRB) faces its own legal problems: a possible lawsuit by the SEC, legal action by a disgruntled employee who is demanding unpaid wages and former landlords looking for $1.8 million in unpaid rent. But the 7-person biotech is also looking to launch some litigation of its own, according to a recent document it filed with the SEC […]
EMA committee backs Amgen’s on-body injector for Neulasta
Amgen (NSDQ:AMGN) said today that a committee for the European Medicines Agency has recommended that the regulatory body approve a label variation for its Neulasta product to include the Onpro on-body injector delivery device. Neulasta’s Onpro kit includes a pre-filled syringe paired with a single-use on-body injector. The lightweight device is given to the patient on the […]
Halyard Health posts Street-beating Q4, full-year results
Shares in Halyard Health (NYSE:HYH) fell slightly today after the medical device maker met expectations on Wall Street with its fourth quarter and full-year finances. The company is in the middle of a $710 million divestiture of its surgical and infectious disease prevention business to Owens & Minor (NYSE:OMI), so it reported financial results for both on-going […]
Abbott, Surmodics ink $25m deal for drug-coated balloon tech
Abbott (NYSE:ABT) is slated to pay $25 million upfront for the global commercialization rights to Surmodics‘ (NSDQ:SRDX) SurVeil drug-coated balloon, the companies announced today. The company’s drug-device combo, which is in pivotal trials in the U.S., is designed to treat peripheral artery disease in the superficial femoral artery. According to the deal, Abbott could also negotiate agreements […]
Medtronic thinks these clinics could be the future of diabetes care – here’s why
Managing a chronic illness can feel like a full-time job. Between juggling multiple appointments with an array of specialists and following a meticulous care plan, patients dealing with conditions like diabetes have a lot on their plate. Medtech titan Medtronic (NYSE:MDT) wants to help change that. The company’s CEO, Omar Ishrak, placed his faith in value-based care as the […]
Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018
Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. Get the full story at our sister site, Drug Delivery Business News.
Lilly touts Ph3 data for once-weekly Type II diabetes medication
Eli Lilly (NYSE:LLY) touted data today from a Phase IIIb study of its once-weekly, injectable Type II diabetes medication, Trulicity. The insulin-maker reported that its GLP-1 receptor agonist significantly improved blood sugar control in people with Type II diabetes when added to ongoing treatment with a SGLT-2 inhibitor. Get the full story at our sister site, […]
Patent board rules Mohawk tribe is not immune to challenges over Restasis IP
The U.S. Patent Trial and Appeal Board ruled last week that the tribal immunity granted to Native American tribes in the U.S. does not shield tribes from patent challenges. The ruling is a setback for Allergan (NYSE:AGN); the pharmaceutical company transferred patent rights for its blockbuster eye drug, Restasis, to the St. Regis Mohawk Tribe last year […]